Latest / Conversations in Lung Cancer Research
Navigating Resistance in ALK-Positive NSCLC Patients on TKI Therapy
We have witnessed incredible advances in therapy since ALK was discovered in 2007, starting from the pivotal PROFILE 1001 study of crizotinib in advanced ALK positive NSCLC to present day where we now have five approved targeted agents, with increasing potency, selectivity and CNS activity with each successive generation of drug. Despite these advances in therapy, the emergence of treatment resistance in the TKI still remains one of greatest challenges in the clinic. Our TOGA podcast panel discuss the clinical and genetic factors affecting treatment choice, sequencing and resistance patterns…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.